USANA Health Sciences (NYSE:USNA) Reaches New 52-Week Low on Analyst Downgrade

Shares of USANA Health Sciences, Inc. (NYSE:USNA) reached a new 52-week low during trading on Thursday after DA Davidson lowered their price target on the stock from $38.00 to $36.00. DA Davidson currently has a neutral rating on the stock. USANA Health Sciences traded as low as $29.99 and last traded at $29.65, with a volume of 28871 shares trading hands. The stock had previously closed at $33.21.

USNA has been the subject of a number of other reports. Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Pzena Investment Management LLC lifted its stake in shares of USANA Health Sciences by 3.6% in the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock valued at $39,015,000 after purchasing an additional 37,466 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in USANA Health Sciences by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock valued at $27,751,000 after buying an additional 55,059 shares during the period. Pacer Advisors Inc. lifted its position in USANA Health Sciences by 8.8% in the fourth quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock valued at $21,247,000 after buying an additional 47,745 shares during the last quarter. State Street Corp boosted its stake in USANA Health Sciences by 0.6% during the third quarter. State Street Corp now owns 435,164 shares of the company’s stock worth $16,501,000 after buying an additional 2,782 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of USANA Health Sciences by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 301,949 shares of the company’s stock valued at $10,839,000 after acquiring an additional 4,829 shares during the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Stock Performance

The business’s 50 day moving average price is $33.50 and its 200-day moving average price is $36.56. The firm has a market capitalization of $544.54 million, a PE ratio of 10.10, a P/E/G ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. As a group, analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.